Univariate linear regression for day 180 EASIX day (log base 2)
| . | Combined cohort . | |
|---|---|---|
| log2 Difference (95% CI) . | P . | |
| CD34+-selected graft | −0.15 (−0.52 to 0.23) | .445 |
| Age (per 10 years) | 0.01 (−0.13 to 0.15) | .899 |
| Male | 0.51 (0.17-0.86) | .004 |
| Donor Type | ||
| Mismatched | (reference) | |
| MRD | −0.44 (−0.97 to 0.08) | .098 |
| MUD | −0.82 (−1.33 to −0.31) | .002 |
| Conditioning intensity | ||
| MAC | (reference) | |
| NMA | 0.32 (−0.09 to 0.73) | .128 |
| RIC | −0.44 (−1.08 to 0.19) | .172 |
| Grade 2-4 aGVHD day 180 | 0.78 (0.41-1.16) | < .001 |
| Grade 3-4 aGVHD day 180 | 1.05 (0.49-1.62) | < .001 |
| Pre-EASIX (per unit) | 0.01 (−0.04 to 0.07) | .71 |
| HCT-CI | ||
| 0-1 | (reference) | |
| 2-3 | 0.53 (0.11-0.95) | .014 |
| 4+ | 0.52 (0.09-0.95) | .018 |
| KPS >80 | −0.05 (−0.41 to 0.31) | .798 |
| Patient CMV+ | −0.12 (−0.47 to 0.22) | .478 |
| Disease | ||
| Acute leukemia | (reference) | |
| Lymphoma | 0.27 (−0.14 to 0.68) | .2 |
| MDS | 0.17 (−0.3 to 0.64) | .473 |
| . | Combined cohort . | |
|---|---|---|
| log2 Difference (95% CI) . | P . | |
| CD34+-selected graft | −0.15 (−0.52 to 0.23) | .445 |
| Age (per 10 years) | 0.01 (−0.13 to 0.15) | .899 |
| Male | 0.51 (0.17-0.86) | .004 |
| Donor Type | ||
| Mismatched | (reference) | |
| MRD | −0.44 (−0.97 to 0.08) | .098 |
| MUD | −0.82 (−1.33 to −0.31) | .002 |
| Conditioning intensity | ||
| MAC | (reference) | |
| NMA | 0.32 (−0.09 to 0.73) | .128 |
| RIC | −0.44 (−1.08 to 0.19) | .172 |
| Grade 2-4 aGVHD day 180 | 0.78 (0.41-1.16) | < .001 |
| Grade 3-4 aGVHD day 180 | 1.05 (0.49-1.62) | < .001 |
| Pre-EASIX (per unit) | 0.01 (−0.04 to 0.07) | .71 |
| HCT-CI | ||
| 0-1 | (reference) | |
| 2-3 | 0.53 (0.11-0.95) | .014 |
| 4+ | 0.52 (0.09-0.95) | .018 |
| KPS >80 | −0.05 (−0.41 to 0.31) | .798 |
| Patient CMV+ | −0.12 (−0.47 to 0.22) | .478 |
| Disease | ||
| Acute leukemia | (reference) | |
| Lymphoma | 0.27 (−0.14 to 0.68) | .2 |
| MDS | 0.17 (−0.3 to 0.64) | .473 |
aGVHD, acute graft-versus-host disease; CMV, cytomegalovirus; HCT-CI: hematopoietic cell transplantation-specific comorbidity index; KPS, Karnofsky performance status; MAC, myeloablative conditioning; MRD, matched related donor; MUD, matched unrelated donor; NMA, nonmyeloablative conditioning; RIC, reduced intensity conditioning.